DEXLANSOPRAZOLE | A202666 | TWI PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Takeda Pharmaceutical Co., Ltd. et al v. TWi Pharmaceuticals, Inc. 1 patentANDA 202666dexlansoprazole | N.D. Cal. | 2013-05-29 | Terminated 2015-06-08 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$4.16
per ea
Lowest NADAC/Unit
$3.84
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 24979000106DEXLANSOPRAZOLE DR 30 MG CAP | $4.16 | EA | Generic | — | 2026-06-17 |
| 24979000206DEXLANSOPRAZOLE DR 60 MG CAP | $3.84 | EA | Generic | — | 2026-06-17 |
| 24979000207DEXLANSOPRAZOLE DR 60 MG CAP | $3.84 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.